MedTrace Logo

Effects of an Acute Dose of Caffeine on the Performance of CrossFit Athletes

NCT06891469 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-03-26

No results posted yet for this study

Summary

The goal of this clinical trial was to investigate the effect of an acute dose of caffeine on CrossFit performance in young, healthy male CrossFit athletes. The main questions it aimed to answer were whether an acute dose of caffeine, compared to placebo:

* Can improve performance in a specific CrossFit workout
* Leads to a reduction in the Rating of Perceived Exertion
* Leads to an increase in blood lactate concentration at the end of the workout

Participants had to:

* Complete two sessions of a specific CrossFit training program (four rounds of five exercises, 50 seconds of exercise/10 seconds of rest), 60 minutes after consuming either anhydrous caffeine (7.1 ± 0.7 mg/kg of body mass) or an equivalent amount of placebo, aiming to perform as many repetitions as possible.
* Report subjective perception of fatigue using the Borg scale at the end of each round.

Conditions

  • Healthy, Young Adults
  • Athletic Performance

Interventions

DIETARY_SUPPLEMENT

Caffeine administration according to body mass (moderate intake- 7 mg/kg)

This randomized, double-blind, crossover study aimed to investigate the acute effects of caffeine consumption on physiological responses and performance during a strength-focused CrossFit workout. Participants will consume either anhydrous caffeine (7.1 ± 0.7 mg/kg of body mass) or placebo, 60 minutes before a CrossFit workout aiming to perform as many repetitions as possible.

DIETARY_SUPPLEMENT

Placebo (Biotin Capsules)

Consumption of biotin (BIOTIN tablets by Myprotein) at the same time as caffeine.

Sponsors & Collaborators

  • Democritus University of Thrace

    lead OTHER

Principal Investigators

  • ILIAS SMILIOS, Professor · Democritus University of Thrace

  • VASSILIS MOUGIOS, Professor · Aristotle University Of Thessaloniki

  • GREGORY C. BOGDANIS, Professor · Gregory C. Bogdanis National and Kapodistrian University of Athens, School of Physical Education and Sport Science

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-22
Primary Completion
2022-05-29
Completion
2022-05-29

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06891469 on ClinicalTrials.gov